Merck: Studies boost Gardasil for new uses

WHITEHOUSE STATION, N.J. (AP) - New studies show that Merck's Gardasil vaccine protects most young women from cervical cancer and homosexual men from anal cancer.

By: Associated Press | WNCT-On Your Side
Published: February 17, 2010

» Comments | Post a Comment

WHITEHOUSE STATION, N.J. (AP) - New studies show that Merck's Gardasil vaccine protects most young women from cervical cancer and homosexual men from anal cancer.
The vaccine is designed to block four of the most common strains of the sexually transmitted human papilloma virus, or HPV.
Gardasil is already approved for preventing cervical cancer and genital warts in females aged 9 to 26, and for preventing genital warts in males aged 9 to 26.
One of the new studies shows Gardasil is about 89 percent effective in blocking cervical cancer, genital warts and lingering HPV infections in women aged 24 to 45. The other shows it is about 77 percent effective in blocking anal cancer and precancerous lesions in homosexual men.
Merck will seek approval to sell the vaccine for those uses. It funded both studies.

Reader Comments

*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.

Deal of the Day

Interactive Radar

Caught On Camera

Hundreds of Marilyn Monroe look-a-likes gather to break world record

A bear and moose take the path less traveled and hundreds of Marilyn Monroe look-a-likes try to break a record. The latest video and stories that will have you talking are coming up now in Take a Look At This!